Related Experiment Video
Updated: Aug 7, 2026

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F
R Eleopra1, V Tugnoli, R Quatrale
1Clinical Neuroscience Department, Neurology Section, Umberto I Hospital, Venice, Italy. roberto.eleopra@ulss12.ve.it
Abstract:
Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit but with short lasting effects. Recently, BoNT serotype C has been used with positive clinical outcome. An update on the clinical use of BoNT serotype F and BoNT serotype C is provided.
More Related Videos
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Botulism
Skeletal Muscle Relaxants: Therapeutic Uses
Tetanus
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...

